🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry (Durbin et al.) go.nature.com/2nUccVA

“Max deserves a cure. He’s just an eight year old kid who wants to play ball.” -Michael, dad of Dana-Farber patient Max, 8 ⚾️ Help us #KCANCER with the Red Sox! jimmyfund.gives/c6a4h

.The Cancer Dependency Map scientists and colleagues have mapped genetic dependencies in pediatric cancers and found many that are unique to these cancers -- suggesting new avenues for drug development. broad.io/PediatricDepMap

Pediatric cancer was underrepresented in The Cancer Dependency Map. We teamed up with pediatric cancer investigators to profile cell lines from 13 pediatric tumors. Excited to share the results of the analysis led by Neekesh V. Dharia, MD PhD. 1/5 nature.com/articles/s4158…

A first-generation pediatric cancer dependency map (Dharia et al.) go.nature.com/3tIbqe0

Targeted treatments exist for only ~ 1/4 of children with #cancer. That’s poised to change with the Pediatric Cancer Dependency Map, just published in Nature Genetics: ms.spr.ly/6011VOQDN cc: Dana-Farber/Boston Children's

A new study published in Nature Genetics by researchers from Dana-Farber/Boston Children's and Broad Institute is the first comprehensive view of the differences in genetic dependencies between pediatric and adult cancers (via Medical Xpress): ms.spr.ly/6013VuV41 Cc: Neekesh V. Dharia, MD PhD #childhoodcancer

Genome-scale CRISPR–Cas9 screening of 82 paediatric cancer cell lines were subjected reveals genes required for cell survival, leading to a 1st-gen pediatric cancer dependency map. Vulnerabilities observed were often distinct from those of adult cancers: nature.com/articles/s4158…

By performing genome-scale screening in childhood tumours, scientists have uncovered clues to the tumours’ potential Achilles heels — but have also learnt that paediatric cancers have unique vulnerabilities not present in adult tumours. #ResearchHighlight go.nature.com/3mAxq88

ICYMI nature #ResearchHighlight Quirks of kids’ cancers are revealed — and could shape hunt for drugs nature.com/articles/d4158… 😍Original article in Nature Genetics here: nature.com/articles/s4158…

Recently published #OnlineFirst: Selective modulation of a pan-essential protein as a therapeutic strategy in cancer. Dana-Farber Boston Children's Broad Institute #SyntheticLethality bit.ly/3tHcXkP

Very excited that my work on TRIM8 in #Ewing sarcoma is now published in @CancerCell cell.com/cancer-cell/fu… #openaccess#pediatric#cancer#selective#dependency#fusion#oncoprotein#stability#degradation Dana-Farber Dana-Farber/Boston Children's

Congratulations to post-doc Alex Seong and team on the publication of this exciting work at Cancer Cell!

Online Now: TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma dlvr.it/S4hKVy

Adrian Sacher, M.D. presenting on #KRAS targeting G12C with oral TKI GDC6036 at the oral session #LCSM #WCLC22 IASLC KRASKickers

GDC6036 covalent KRAS G12C. FIH data NSCLC cohort. Prior G12C therapy excluded. N=59. Nausea vomiting and diarrhea commonest AEs usually low grade. 7% g3 ALT elevation. Expansion dose 400mg OD. cORR 46%. Impressive spider plots. Looking forward to more mono & combo data #WCLC22

Dr. Adrian Sacher, M.D. presents impressive data on GDC-6036 in #KRAS G12C NSCLC - clearly active with confirmed RR 46% and some quite durable responses. Field getting more crowded. #WCLC22

The KRAS G12C inhibitor GDC-6036 conveys confirmed ORR 46%, early reported duration of response and depth of responses need further follow-up, excelente présentation by Dr. Adrian Sacher IASLC #WCLC22

First data of GDC-6036, a KRAS G12C inhibitor. Confirmed ORR 26/57 (46%) but note that this might be higher if limited to patients treated at the R2PD (400mg). Predominant GI and liver tox, seems manageable. Promising but enough to get PFS>10 months? #WCLC2022

"It's never over. You continue with your scans, and you wait and you hold your breath, but that's why we do this." Lisa Scherber on Max Mitchell, a 12-year-old diagnosed with Ewing Sarcoma at age 5 and has persevered through treatment ever since. The Jimmy Fund | Tom Caron